195 related articles for article (PubMed ID: 31760573)
1. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.
Tothova Z; Steensma DP; Ebert BL
Clin Cancer Res; 2013 Apr; 19(7):1637-43. PubMed ID: 23329810
[TBL] [Abstract][Full Text] [Related]
2. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.
Frumm SM; Shimony S; Stone RM; DeAngelo DJ; Bewersdorf JP; Zeidan AM; Stahl M
Blood Rev; 2023 Jul; 60():101056. PubMed ID: 36805300
[TBL] [Abstract][Full Text] [Related]
3. [Epigenetic dysregulation and emerging treatment strategies in myelodysplastic syndromes].
Kunimoto H
Rinsho Ketsueki; 2024; 65(5):362-374. PubMed ID: 38825515
[TBL] [Abstract][Full Text] [Related]
4. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1
Bewersdorf JP; Xie Z; Bejar R; Borate U; Boultwood J; Brunner AM; Buckstein R; Carraway HE; Churpek JE; Daver NG; Porta MGD; DeZern AE; Fenaux P; Figueroa ME; Gore SD; Griffiths EA; Halene S; Hasserjian RP; Hourigan CS; Kim TK; Komrokji R; Kuchroo VK; List AF; Loghavi S; Majeti R; Odenike O; Patnaik MM; Platzbecker U; Roboz GJ; Sallman DA; Santini V; Sanz G; Sekeres MA; Stahl M; Starczynowski DT; Steensma DP; Taylor J; Abdel-Wahab O; Xu ML; Savona MR; Wei AH; Zeidan AM
Blood Rev; 2023 Jul; 60():101072. PubMed ID: 36934059
[TBL] [Abstract][Full Text] [Related]
5. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments.
Kontandreopoulou CN; Kalopisis K; Viniou NA; Diamantopoulos P
Front Oncol; 2022; 12():989483. PubMed ID: 36338673
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Landscape: Exploring the Future of Myelodysplastic Syndrome Treatment with Dr. Rami Komrokji.
Jackewicz SH; Coloma HS; Cortiana V; Joshi M; Menon GP; Balasubramanian M; Park CH; Leyfman Y
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958344
[TBL] [Abstract][Full Text] [Related]
7. Emerging Therapies for the Myelodysplastic Syndromes.
Canaani J
Clin Hematol Int; 2020 Mar; 2(1):13-17. PubMed ID: 34595438
[TBL] [Abstract][Full Text] [Related]
8. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
9. International scoring system for evaluating prognosis in myelodysplastic syndromes.
Greenberg P; Cox C; LeBeau MM; Fenaux P; Morel P; Sanz G; Sanz M; Vallespi T; Hamblin T; Oscier D; Ohyashiki K; Toyama K; Aul C; Mufti G; Bennett J
Blood; 1997 Mar; 89(6):2079-88. PubMed ID: 9058730
[TBL] [Abstract][Full Text] [Related]
10. Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes.
Lee SE; Wang F; Trujillo-Ocampo A; Ruiz-Vasquez W; Cho HW; Takahashi K; Molldrem JJ; Futreal A; Garcia-Manero G; Im JS
EJHaem; 2020 Nov; 1(2):552-557. PubMed ID: 35844984
[TBL] [Abstract][Full Text] [Related]
11. The functional mechanisms of mutations in myelodysplastic syndrome.
Nagata Y; Maciejewski JP
Leukemia; 2019 Dec; 33(12):2779-2794. PubMed ID: 31673113
[TBL] [Abstract][Full Text] [Related]
12. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
14. Mutation-Driven Therapy in MDS.
Swoboda DM; Sallman DA
Curr Hematol Malig Rep; 2019 Dec; 14(6):550-560. PubMed ID: 31760573
[TBL] [Abstract][Full Text] [Related]
15. Targeting TP53 Mutations in Myelodysplastic Syndromes.
Hunter AM; Sallman DA
Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
[TBL] [Abstract][Full Text] [Related]
16. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
